Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes.
OBJECTIVE
This study evaluated the clinical features and treatment outcomes in patients with endogenous Aspergillus endophthalmitis.


METHODS
The study design was a multicenter retrospective chart review.


METHODS
Ten patients (12 eyes) with culture-proven endogenous Aspergillus endophthalmitis treated by 1 of the authors were studied.


METHODS
Intravitreous amphotericin B injection, pars plana vitrectomy, systemic amphotericin B therapy, and oral anti-fungal therapy were performed.


METHODS
Elimination of endogenous Aspergillus endophthalmitis and Snellen visual acuity, best corrected, were measured.


RESULTS
All patients had a 1- to 3-day history of pain and marked loss of visual acuity in the involved eyes. Varying degrees of vitritis was present in all 12 eyes. In 8 of 12 eyes, a central macular chorioretinal inflammatory lesion was present. Four patients (six eyes) had associated pulmonary diseases and were receiving concurrent steroid therapy. One of these patients with chronic asthma also was abusing intravenous drugs. Overall, six patients (six eyes) had a history of intravenous drug abuse, whereas a seventh patient (one eye) was suspected of abusing intravenous drugs. Blood cultures and echocardiograms were negative for systemic aspergillosis. Management consisted of a pars plana vitrectomy in 10 of 12 eyes. Intravitreous amphotericin B was administered in 11 of 12 eyes. Systemic amphotericin B therapy was used in eight patients. One patient was treated with oral antifungal agents. In three eyes without central macular involvement, final visual acuities were 20/25 to 20/200. In eight eyes with initial central macular involvement, final visual acuities were 20/400 in three eyes and 5/200 or less in four eyes. Two painful eyes with marked inflammation, hypotony, and retinal detachment were enucleated.


CONCLUSIONS
Endogenous Aspergillus endophthalmitis usually has an acute onset of intraocular inflammation and often has a characteristic chorioretinal lesion located in the macula. Although treatment with pars plana vitrectomy and intravitreous amphotericin B is capable of eliminating the ocular infection, the visual outcome generally is poor, especially when there is direct macular involvement.
Weishaar
P D
PD
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, FL 33136, USA.
Flynn
H W
HW
Murray
T G
TG
Davis
J L
JL
Barr
C C
CC
Gross
J G
JG
Mein
C E
CE
McLean
W C
WC
Killian
J H
JH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D001231:Aspergillus flavus / Q000302:isolation & purification; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D001249:Asthma / Q000150:complications; D009877:Endophthalmitis / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015821:Eye Infections, Fungal / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008173:Lung Diseases, Obstructive / Q000150:complications; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
D000935:Antifungal Agents; D000666:Amphotericin B